Table 2:
Summary of median durability of ART regimen by regimen class, composition, and year of initiation in treatment naïve HIV patients initiating care in a multi-site cohort
| Class of ART backbone | Treatment share N (%) | Median durability, months (95% CI) |
| Integrase Inhibitor | 1110 (21) | 44 (40, 57) |
| Integrase Inhibitor/Protease Inhibitor | 76 (1) | 18 (10, 24) |
| Non-nucleoside reverse transcriptase inhibitor | 2637 (49) | 61 (56, 65) |
| Protease Inhibitor | 1547 (29) | 32 (29, 35) |
| ART regimen composition | Treatment share N (%) | Median durability, months (95% CI) |
| Dolutegravir/abacavir/lamivudine | 106 (2) | 9!, * |
| Atazanavir/ritonavir/emtricitabine/tenofovir/r | 665 (12) | 36 (31,42) |
| Darunavir/ritonavir/emtricitabine/tenofovir | 546(10) | 41 (36, 47) |
| Dolutegravir/emtricitabine/tenofovir | 89 (2) | 5!, 22! |
| Efavirenz/emtricitabine/tenofovir | 2173 (40) | 62 (56,65) |
| Elvitegravir/cobicistat/emtricitabine/tenofovir | 571 (11) | 33!, * |
| Raltegravir/emtricitabine/tenofovir | 286 (5) | 43 (36,57) |
| Rilpivirine/emtricitabine/tenofovir | 336 (6) | 70 (47, *) |
| Other | 601 (11) | 18 (15,22) |
| Year of ART regimen initiation |
Treatment Share N (%) |
Median durability, months (95% CI) |
| 2007–2009 | 1882 (35) | 56 (51,61) |
| 2010–2012 | 2135 (40) | 44 (42,47) |
| 2013–2015 | 1356 (25 ) | 11!, 31! |
Median durability calculated using Kaplan-Meier survival curves
!
Point estimate not estimable thus 25th and 75th percentile is shown
*
75th percentile is not estimable